DAFTAR PUSTAKA
Armstrong AW, Harskamp CT, Armstrong EJ (2013). Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol., 68(4):654-662.
Budiastuti A (2011). Korelasi kadar TNF ɑ dan skor Psoriasis Area Severity Index (PASI) pada pasien psoriasis. Media Medika Indonesiana, 45(2): 10-15.
Cantika AS (2012). Hubungan derajat keparahan psoriasis terhadap kualitas hidup penderita. Jurnal Universitas Diponegoro, 17: 32-40.
Cohen AD, Sherf M, Vidavsky L, Shapiro J, Meyerovitch J (2008). Association between psoriasis and metabolic syndrome. Dermatology on Kargel Medicine Journal, 216: 152-155.
Coumbe AG, Pritzker MR, Duprez DA (2014). Cardiovascular Risk and Psoriasis:
Beyond the traditional Risk Factor. Am J Med., 127: 12-18.
Dahlan MS (2014). Langkah-langkah membuat proposal penelitian bidang kedokteran dan kesehatan. Jakarta: Sagung Seto.
Deny F, Lestari S, Isramiharti, Zainal, Salmiah A (2004). Respon klinis dan histologik pada psoriasis vulgaris tipe plak rekalsitran yang diterapi metotreksat di RS Dr.M.Djamil Padang. Majalah Kedokteran Universitas Andalas, 28(2): 1-4.
Djuanda A (2007). Dermatosis eritroskuamosa. Dalam: Djuanda A, Hamzah M, Alsah S (eds). Ilmu Penyakit Kulit dan Kelamin. Edisi ke 5. Jakarta: Fakultas Kedokteran Universitas Indonesia.
D’ Costa G, Bharambe BM (2010). Spectrum of non-infectious erythematous, papular, and squamous lesions of the skin. In J Dermatol., 45(2): 119-127.
Fry L (2004). An atlas of psoriasis. Edisi ke 2. London and New York: Taylor and Francis group.
Gerdes S, Zahl VA, Weichenthal M, Mrowietz U (2009). Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology on Kargel Medicine Journal, 220: 38-43.
Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M (2010). Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci., 7(5):
284-9.
Griffiths C, Barker JNWN (2010). Psoriasis. Dalam: Burns T, Breathnach S, Cox N, Griffiths C. Rook's Dermatology. Edisi ke 7. Oxford: Blackwell Publishing.
Gudjonsson J, Elder J (2012). Psoriasis. Dalam: Wolff K, Katz S, Gilchrest B, Paller A, Leffel D (eds). Fitzpatrick dermatology in general medicine. Edisi ke 8.
New York: McGraw Hill.
Guyton dan Hall (2012). Fisiologi Kedokteran. Edisi ke 11. Jakarta: Elsevier.
Hendry (2013). Gambaran tekanan darah pada pasien psoriasis vulgaris di poliklinik kulit dan kelamin RSUP H. Adam Malik Medan. Jurnal Universitas Sumatera Utara, 15(2): 4.
Hsu S, Papp K, Lebwohl M, Bagel J, Blauvelt A, Duffin K, et al. (2012). Consensus guidelines for the management of plaque psoriasis. Arch Dermatol., 148:
95–102.
James WD, Berger TG, Elston DM (2006). Andrews’ disease of the skin: clinical dermatology. Edisi ke 10. Philadelphia: Elsevier.
Jean LB, Joseph LJ, Ronald PR (2008). Bolognia dermatology. Edisi ke 2. Oxford:
Elsevier.
Joint National Committee 7 (2003). ESH-ESC guidelines for the management of arterial hypertension. JNC 7., 21: 1011-1053.
Kalkan G, Karadag AS (2013). The association between psoriasis and cardiovascular diseases. Eur J Gen Med., 10: 10-6.
Kamalpour L, Perry A, Hill N (2010). Body surface area as a measure of psoriasis-associated cardiovascular disease risk. J Am Acad Dermatol., 62(3)(1): AB68.
Kremes HM, Mc Evoy MT, Dann FJ, Gabriel SE (2007). Heart disease in psoriasis. J Am Acad Dermatol., 57(2): 347-354.
Leonardi C, Gu Y, Arikan D, Lau W, Amer F (2015). Cardiovascular risk factors in patients with moderate to severe psoriasis: Integrated prevalence and safety data from 5 randomized controlled trials of adalimumab. J Am Acad Dermatol., 72(5)(1): AB227.
Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC et al. (2012).
Ma C, Harskamp CT, Armstrong EJ, Armstrong AW (2013). The association between psoriasis and dyslipidemia: A systematic review. Br J Dermatol., 168(3):
486-495.
Mallbris L, Granath F, Hamsten A, Ståhle M (2006). Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol., 54: 614-621.
Miller IM, Ellervik C, Yazdanyar S, Jemec GBE (2013). Meta-analysis of psoriasis, cardiovascular disease, and associated risk factor. J Am Acad Dermatol., 69(6):
1014-1024.
Natali (2012). Profil kadar prolaktin serum pada berbagai derajat keparahan penderita psoriasis vulgaris di RSUP H. Adam Malik Medan. Repositori USU, 28: 1-9.
Neimann LA, Gelfand MJ, Shin BD, Wang X, Margolis DJ, Troxel BA (2006). Risk of myocardial infarction in patients with psoriasis. J Am Acad Dermatol., 98(2):
1735-1741.
Ogdie A, Yu Y, Hayens K, Love TJ, Maliha S, Jiang Y et al. (2015). Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Br J dermatol., 74(2):
336-342.
Perdanakusuma DS (2007). Anatomi fisiologi kulit dan penyembuhan luka. Surabaya:
Airlangga University Press.
Pietrzak A, Michalak SA, Chodorowska G, Szepietowski J (2010). Lipid disturbances in psoriasis: An update mediators of inflammation, J Am Acad Dermatol., 76(2): 1-13.
Ryan C, Kirby B (2015). Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin., 33(1): 41-55.
Sastroasmoro S, Ismael S (2014). Dasar-dasar metodologi penelitian klinis. Edisi ke 5. Jakarta: Fakultas Kedokteran Universitas Indonesia.
Saurat JH, Guerin A, Yu A, Latremouille-viau D, Wu EQ, Gupta SR et al. (2010).
High prevalence of potential drug interactions for psoriasis patients prescribed methotrexate or cyclosporin for psoriasis: Associated clinical and economic outcomes in real world practice. Dermatology on Kargel Medicine Journal, 220(1): 128-137.
Setyorini M, Triestianawati W, Wiryadi BE, Jacoeb TNA (2010). Proporsi sindrom metabolik pada pasien psoriasis vulgaris berdasarkan kriteria national cholesterol education program adult treatment panel III di RS Dr. Cipto Mangunkusumo. MDVI., 39(1): 2-9.
Shapiro J, Cohen AD, Weitzman D, Tal R, David M (2012). Psoriasis and cardiovascular risk factors: A-case control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol., 72 (5): AB227.
Sherwood, L (2010). Human Physiology from cells to systems. Edisi ke 7. USA:
Cengage Learning.
Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB, Gelfand (2006).
Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol., 55(5): 829-835.
Singh G, Aneja SPS (2011). Cardiovascular comorbidity in psoriasis. Indian J Dermatol., 56(5): 553-6.
Sommer DM, Jenisch S, Christophers SM, Weichenthal M (2006). Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res., 298: 321-328.
Suherman SK, Ascobat P (2009). Farmakologi dan terapi. Edisi kelima. Jakarta:
Fakultas Kedokteran Universitas Indonesia.
Suhoyo (2015). Hubungan kadar nitric oxide serum pasien psoriasis vulgaris dengan skor psoriasis area and severity index. Repositori USU, 33(1): 9.
Takahashi H, Lizuka H (2010). Psoriasis and metabolic syndrome. J Am Acad Dermatol., 38: 1-7.
Teixera A,Gil A, Siva AP, Filipe P (2016). Susceptibility to psoriasis associated to cardiovascular risk genotype. J Am Acad Dermatol., 74: AB276.
Thamtono Y (2016). Hubungan psoriasis dengan komorbiditas kardiovaskular.
CDK-237., 43(2): 1-8.
Traub M, Marshall K (2007). Psoriasis – pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev., 12: 319-330.
WHO (2016). Global report on psoriasis. World Health Organization.
Wu J, Guerin A, Sundaram M (2016). Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor alpha inhibitors versus phototherapy. J Am Acad Dermatol., 74(5)(1): AB238.
Wu Y, Wang Y, Yeilding N (2007). Prevalence of cardiovascular risk factors and other comorbidities among psoriasis patients. J Am Acad Dermatol., 56(1)(2):
AB191.
Zulkarnain D (2015). Profil pasien psoriasis vulgaris di poliklinik RSUP Dr. M.
Djamil Padang periode 1 Januari 2011-31 Desember 2014. E Skripsi Universitas Andalas, 4(2): 1-5.
